Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer.
D'Arcangelo M, D'Incecco A, Ligorio C, Damiani S, Puccetti M, Bravaccini S, Terracciano L, Bennati C, Minuti G, Vecchiarelli S, Landi L, Milesi M, Meroni A, Ravaioli S, Tumedei MM, Incarbone M, Cappuzzo F. D'Arcangelo M, et al. Among authors: d incecco a. Oncotarget. 2019 Jan 15;10(5):561-572. doi: 10.18632/oncotarget.26529. eCollection 2019 Jan 15. Oncotarget. 2019. PMID: 30728907 Free PMC article.
Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC).
Vecchiarelli S, Passiglia F, D'Incecco A, Gallo M, De Luca A, Rossi E, D'Incà F, Minuti G, Landi L, Bennati C, Spreafico M, D'Arcangelo M, Mazza V, Normanno N, Cappuzzo F. Vecchiarelli S, et al. Among authors: d incecco a. Oncotarget. 2018 Apr 3;9(25):17554-17563. doi: 10.18632/oncotarget.24785. eCollection 2018 Apr 3. Oncotarget. 2018. PMID: 29707129 Free PMC article.
Gefitinib for non-small-cell lung cancer treatment.
D'Incecco A, Cappuzzo F. D'Incecco A, et al. Expert Opin Drug Saf. 2011 Nov;10(6):987-96. doi: 10.1517/14740338.2011.617738. Epub 2011 Sep 12. Expert Opin Drug Saf. 2011. PMID: 21905963 Review.
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.
D'Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, Tibaldi C, Minuti G, Salvini J, Coppi E, Chella A, Fontanini G, Filice ME, Tornillo L, Incensati RM, Sani S, Crinò L, Terracciano L, Cappuzzo F. D'Incecco A, et al. Br J Cancer. 2015 Jan 6;112(1):95-102. doi: 10.1038/bjc.2014.555. Epub 2014 Oct 28. Br J Cancer. 2015. PMID: 25349974 Free PMC article.
Rare mutations in non-small-cell lung cancer.
D'Arcangelo M, D'Incecco A, Cappuzzo F. D'Arcangelo M, et al. Future Oncol. 2013 May;9(5):699-711. doi: 10.2217/fon.13.16. Future Oncol. 2013. PMID: 23647298 Review.
Protein kinase inhibitors to treat non-small-cell lung cancer.
Minuti G, D'Incecco A, Landi L, Cappuzzo F. Minuti G, et al. Expert Opin Pharmacother. 2014 Jun;15(9):1203-13. doi: 10.1517/14656566.2014.909412. Epub 2014 Apr 19. Expert Opin Pharmacother. 2014. PMID: 24745764 Review.
Targeted therapy for NSCLC with driver mutations.
Minuti G, D'Incecco A, Cappuzzo F. Minuti G, et al. Expert Opin Biol Ther. 2013 Oct;13(10):1401-12. doi: 10.1517/14712598.2013.827657. Epub 2013 Aug 10. Expert Opin Biol Ther. 2013. PMID: 23930754 Review.
36 results